Comparison of doxazosin GITS and standard doxazosin in the treatment of high blood pressure

被引:0
作者
Os, I [1 ]
机构
[1] Ulleval Hosp, Dept Nephrol, N-0407 Oslo, Norway
关键词
doxazosin; hypertension; GITS; blood pressure; extended release;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To examine (1) the relative therapeutic equivalence of 4 mg doxazosin gastrointestinal therapeutic system (DOX GITS) and 4 mg doxazosin standard (DOX-S4) and (2) the efficacy and safety of 4 mg DOX GITS versus 2 mg doxazosin standard (DOX-S2). Patients: Male or female patients aged 18 - 80 diagnosed with mild-to-moderate essential hypertension (sitting diastolic blood pressure (DBP) 95 - 110 mmHg and systolic blood pressure (SBP) < 180 mmHg) were randomized into the study. Methods: This double-blind, parallel, 9-week trial compared DOX-GITS with doxazosin standard (DOX-S) in 310 hypertensive patients. Following a 2-week placebo run-in phase, patients were randomized to receive DOX-GITS at 4 mg/d or DOX-S at 2 or 4 mg/d. DOX GITS dosage remained unchanged at 4 mg throughout the study. Titration in the DOX-S groups was initiated at Week 0 with 1 mg DOX-S and increased to 2 mg DOX-S at Week 1. Dosage in the DOX-S4 group was increased to 4 mg DOX-S at Week 3. Therapeutic equivalence was measured by the change from baseline in sitting diastolic BP (DBP). Efficacy was assessed using the change from baseline for all blood pressure measures. Safety analysis included evaluation of laboratory tests at clinic visits and adverse events (AEs). Results: Therapeutic equivalences between DOX GITS and DOX-S4 and DOX-S2 were established at all study visits except for a significant difference in favor of DOX GITS at Week 1 (p = 0.019) when the dose of DOX-S was 1 mg. All groups had a significant decrease in BP at all study visits compared with baseline. The proportion of patients who reached goal sitting DBP (< 90 mmHg) was similar among the three treatment groups, except at Week 1, when more patients in the DOX GITS group had obtained the goal compared with those in the DOX-S2 group (40.6% vs. 22.3%; p = 0.005). The proportion of patients who reached sitting SBP (< 140 mmHg) goal was similar among groups. AE profiles among the groups were similar. Conclusion: DOX GITS was as effeclive as DOX-S in patients with mild-to-moderate hypertension. The improved pharmaco-kinetic profile of the GITS formulation compared with the standard formulation allows a therapeutic dose to be delivered earlier and without dose titration. Both formulations of doxazosin were well tolerated.
引用
收藏
页码:99 / 106
页数:8
相关论文
共 27 条
[1]   Diuretic versus α-blocker as first-step antihypertensive therapy -: Final results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) [J].
Alderman, MH .
HYPERTENSION, 2003, 42 (03) :239-246
[2]  
*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981
[3]   The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: A randomized, placebo-controlled study [J].
Black, HR ;
Sollins, JS ;
Garofalo, JL .
AMERICAN JOURNAL OF HYPERTENSION, 2000, 13 (05) :468-474
[4]  
BLACK HR, 2006, IN PRESS J CLIN HYPE
[5]   Doxazosin GITS versus standard doxazosin in mild to moderate hypertension [J].
Calvo, C ;
Gil-Extremera, B ;
Gomez-Fernández, P ;
Masramon, X ;
Pueyo, C ;
Armada, B .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2005, 101 (01) :97-104
[6]   Doxazosin in a gastrointestinal therapeutic system formulation [J].
Cases, A .
DRUGS OF TODAY, 2000, 36 (10) :679-688
[7]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[8]  
Chung M, 1999, BRIT J CLIN PHARMACO, V48, P678
[9]   Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):: a multicentre randomised controlled trial [J].
Dahlöf, B ;
Sever, PS ;
Poulter, NR ;
Wedel, H ;
Beevers, DG ;
Caulfield, M ;
Collins, R ;
Kjeldsen, SE ;
Kristinsson, A ;
McInnes, GT ;
Mehlsen, J ;
Nieminen, M ;
O'Brien, E ;
Östergren, J .
LANCET, 2005, 366 (9489) :895-906
[10]   Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT) [J].
Davis, BR ;
Cutler, JA ;
Gordon, DJ ;
Furberg, CD ;
Wright, JT ;
Cushman, WC ;
Grimm, RH ;
LaRosa, J ;
Whelton, PK ;
Perry, HM ;
Alderman, MH ;
Ford, CE ;
Oparil, S ;
Francis, C ;
Proschan, M ;
Pressel, S ;
Black, HR ;
Hawkins, CM .
AMERICAN JOURNAL OF HYPERTENSION, 1996, 9 (04) :342-360